These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 23932922)

  • 41. [Metabolic mechanisms of different types of disuse muscular atrophy].
    Goncharova LA; Kazarian VA; Shipilova TIu; Rapoport EA
    Vopr Med Khim; 1982; 28(4):105-9. PubMed ID: 6180553
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Muscle type and fiber type specificity in muscle wasting.
    Ciciliot S; Rossi AC; Dyar KA; Blaauw B; Schiaffino S
    Int J Biochem Cell Biol; 2013 Oct; 45(10):2191-9. PubMed ID: 23702032
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Myostatin and its precursor protein are increased in the skeletal muscle of patients with Type-II muscle fibre atrophy.
    Wójcik S; Nogalska A; Engel WK; Askanas V
    Folia Morphol (Warsz); 2008 Feb; 67(1):6-12. PubMed ID: 18335407
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevention of post-stroke disuse muscle atrophy with a free radical scavenger.
    Naritomi H; Moriwaki H
    Front Neurol Neurosci; 2013; 32():139-47. PubMed ID: 23859973
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment of Muscle Wasting: An Overview of Promising Treatment Targets.
    von Haehling S; Springer J
    J Am Med Dir Assoc; 2015 Dec; 16(12):1014-9. PubMed ID: 26593302
    [No Abstract]   [Full Text] [Related]  

  • 46. [Treatment of leprotic amyotrophias with vitamin E].
    SARMENTO VM
    Hospital (Rio J); 1960 Feb; 57():319-35. PubMed ID: 14441773
    [No Abstract]   [Full Text] [Related]  

  • 47. Regulatory Role of MicroRNAs in Muscle Atrophy during Exercise Intervention.
    Zhang S; Chen N
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29385720
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting myostatin for therapies against muscle-wasting disorders.
    Tsuchida K
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):487-94. PubMed ID: 18600566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Molecular mechanisms and treatment options for muscle wasting diseases.
    Rüegg MA; Glass DJ
    Annu Rev Pharmacol Toxicol; 2011; 51():373-95. PubMed ID: 20936944
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Muscle atrophy: from molecular pathways to clinical therapy.
    Kargul J; Laurent GJ
    Int J Biochem Cell Biol; 2013 Oct; 45(10):2119. PubMed ID: 23932922
    [No Abstract]   [Full Text] [Related]  

  • 51. Session on protein metabolism in the elderly. Sarcopenia of the elderly.
    Barazzoni R; Nair KS
    Diabetes Nutr Metab; 2000 Apr; 13(2):92-8. PubMed ID: 10898127
    [No Abstract]   [Full Text] [Related]  

  • 52. Muscle atrophy in rheumatoid arthritis.
    Herbison GJ; Ditunno JF; Jaweed MM
    J Rheumatol Suppl; 1987 Aug; 14 Suppl 15():78-81. PubMed ID: 3309295
    [TBL] [Abstract][Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.